[Transthyretin amyloid cardiomyopathy].

Transthyretin amyloidosis (ATTR-CM) is an infiltrative cardiomyopathy caused by the deposition of amyloid fibrils, leading to heart failure, arrhythmias, and increased mortality. ATTR-CM prevalence is rising. The first disease-modifying drugs have been approved and implemented in Denmark. Additional treatments slowing ATTR-CM progression are pending introduction into clinical practice. Treatments halting or even reversing progression are currently being investigated in clinical trials. The new therapies will significantly improve ATTR-CM-associated morbidity and mortality, as argued in this review.